Taking supernatant home: what the rules actually are

First, the distinction almost everyone misses

Two completely different things are sold under the name “culture supernatant.” One is a cosmetic — a topical serum containing human stem cell conditioned medium, sold over the counter, at a very low concentration, formulated to reach the stratum corneum. The other is the concentrated material a clinic infuses or injects, which acts below the skin.

If someone tells you a friend bought supernatant in Japan and carried it home without trouble, they almost certainly bought the cosmetic. That is a normal retail purchase and normally travels with you. Everything else on this page is about the injectable, which is a different legal object entirely.

Start here: no country has approved one

The Japanese Society for Regenerative Medicine states in its guidance on the clinical application of extracellular vesicles that, as things stand, no country has granted marketing approval to a drug whose main active ingredient is EVs. Japan’s Ministry of Health, Labour and Welfare says the same in its 2024 notice, explicitly including other countries.

That means there is no country in which you can import this as an approved medicine, because in no country is it one. Whatever route someone describes to you, it is not the ordinary route for bringing medication home.

Every country gates this, and hand-carrying is included

Japan’s own rules are a useful model for what to expect at your end. To bring medicines into Japan for personal use — and the rule explicitly covers carrying them in your luggage, not just shipping — you must submit documents to the regional health bureau and obtain an import confirmation. Personal use also means personal: you may not sell or give what you imported to anyone else.

Assume your own country has an equivalent gate, and find out what it is before you fly rather than at the counter. Ask your national health authority, not the clinic and not an agent.

Stability and storage are named risk factors

The same society guidance lists the stability and storage method of EVs, and whether preparation followed GMP or GCTP standards, among the factors that determine risk. A vial that has been through a cabin bag, a security queue, a long flight and a domestic transfer has no documented cold chain behind it.

You would have no way to establish that what arrives is what left. Neither would anyone treating you afterwards.

The guidance assumes a physician administers it

The guidance is written for clinical use by a physician. It contains no provision for handing product to a patient to take away, and none for self-administration. The health ministry’s notice puts the safety responsibility on the treating physician or dentist personally.

If the plan is that you inject yourself at home, you are outside the framework these documents were written for — and if a reaction occurs, no one who understands the product is in the room. A clinic that offers to ship injectable biological material internationally is telling you something about how it manages that risk.

Common questions

The clinic offered to courier further doses to me after I return. Is that normal?

Treat it as a question to escalate, not a convenience. Ask what customs classification they declare it under, what documentation travels with it, and who is responsible if it is seized or arrives degraded. Also ask who would administer it and who is liable if you react. The answers should be in writing.

What if I only want to bring some back for a family member?

Japan’s personal-import rules are explicit that what you import for personal use may not be sold or given to another person, and most countries take the same position. Beyond the legal point, giving an unapproved biological product to someone who was never examined removes the one safeguard the system still has.